STOCK TITAN

Annovis Bio Inc - ANVS STOCK NEWS

Welcome to our dedicated page for Annovis Bio news (Ticker: ANVS), a resource for investors and traders seeking the latest updates and insights on Annovis Bio stock.

Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage pharmaceutical company dedicated to developing novel therapies for neurodegenerative diseases such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Headquartered in Malvern, Pennsylvania, Annovis is pioneering innovative approaches to combat neurodegeneration by targeting multiple neurotoxic proteins simultaneously. The company’s lead compound, Buntanetap (formerly Posiphen or ANVS401), is designed to inhibit the formation of amyloid beta, tau, alpha-synuclein, and TDP43, aiming to improve synaptic transmission and axonal transport while reducing neuroinflammation.

Annovis Bio’s flagship product, Buntanetap, is in phase II/III clinical trials for the treatment of mild to moderate AD and early PD. The drug has shown promising results, demonstrating significant improvements in cognitive function and reducing neurotoxic biomarkers in patients. Alongside Buntanetap, the company is advancing ANVS405 for acute neurodegeneration post-traumatic brain injury and stroke, and ANVS301, currently in phase I trials, aimed at enhancing cognitive capabilities in advanced AD and dementia.

Founded in 2008 by Dr. Maria Maccecchini, Ph.D., Annovis Bio continues to focus on restoring brain function to alleviate symptoms and improve the quality of life for individuals affected by neurodegenerative diseases. The company has established itself as a leader in the field through partnerships, rigorous scientific research, and a commitment to transparency with all stakeholders.

Recent achievements include the completion of a Phase II/III study of Buntanetap in Alzheimer’s patients, demonstrating a statistically significant improvement in cognition and a favorable safety profile. Additionally, Annovis has filed a patent application for the use of Buntanetap in treating neuropsychiatric conditions such as autism and bipolar disorder, highlighting the drug’s versatile potential.

A financial overview reveals that Annovis ended the first quarter of 2024 with $3.1 million in cash, ensuring operational sustainability into the fourth quarter through strategic financial management. The company has actively engaged with the scientific and investment communities, participating in notable conferences like the International Conference on Alzheimer’s and Parkinson’s Diseases and hosting investor calls to discuss clinical milestones and future plans.

For more information about Annovis Bio, visit their website and follow them on LinkedIn and X (formerly Twitter).

Rhea-AI Summary

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company focused on neurodegenerative diseases, announces a live webcast Patients' Forum scheduled for February 27, 2025, at 4:30 PM EST. CEO Maria Maccecchini, Ph.D., will lead the session, addressing questions from patients, caregivers, and families.

The forum will provide updates on several key areas including:

  • Ongoing Phase 3 Alzheimer's disease trial
  • Plans for Phase 3 Parkinson's disease study
  • Open Label Extension studies
  • Patient communication strategies

The event will feature a presentation of recent achievements followed by a Q&A session. Participants can submit questions in advance to clinicaltrials@annovisbio.com. While open to all, the forum is specifically designed for patients, families, and caregivers, demonstrating Annovis's commitment to transparency and patient-centered communication.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Annovis Bio (NYSE: ANVS) has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference. CEO Maria Maccecchini, Ph.D., will deliver a presentation on February 11, 2025, from 12:40 to 1:10 p.m. ET through the conference's virtual platform.

The presentation will focus on the company's recent developments, particularly highlighting progress in their pivotal Phase 3 trial for early Alzheimer's disease. Dr. Maccecchini will also discuss strategic initiatives regarding a New Drug Application (NDA) for buntanetap, which is being developed as both a symptomatic and potentially disease-modifying treatment.

The conference is a significant industry event that connects leading healthcare and life sciences companies with investors, offering a platform for executives to share insights on industry trends, innovations, and investment opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Annovis Bio (NYSE: ANVS) has initiated its pivotal Phase 3 study of buntanetap for early Alzheimer's disease (AD) with the enrollment of the first two patients. The randomized, placebo-controlled, double-blind study will evaluate the drug's safety and efficacy over 18 months, divided into a 6-month assessment of symptomatic effects and a 12-month evaluation of disease-modifying effects.

The study follows positive Phase 2/3 trial results showing significant cognitive improvement in early AD patients with no safety concerns. The company recently raised $21 million through a public offering to fund the initial 6-month portion, with the remaining 12-month phase expected to be funded through warrant exercises.

The trial will enroll over 750 participants across approximately 100 U.S. sites, with primary outcomes measured using the ADAS-Cog13 subscale for cognition and ADCS-iADL scale for functional ability. The first two sites have begun recruiting in Winter Park, FL and Tom's River, NJ.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Annovis Bio (NYSE: ANVS) has completed its previously announced public offering, raising $21 million in gross proceeds. The offering consisted of 5,250,000 shares of common stock and warrants to purchase an additional 5,250,000 shares at a combined price of $4.00 per share and associated warrant. The warrants are immediately exercisable at $5.00 per share for five years.

The company plans to use the net proceeds primarily to fund the Phase 3 clinical development of Buntanetap for Alzheimer's disease, along with working capital and general corporate purposes. ThinkEquity served as the sole book-running manager for the offering, which was conducted under a shelf registration statement on Form S-3.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Annovis Bio (NYSE: ANVS) has announced the pricing of a public offering consisting of 5,250,000 shares of common stock and warrants to purchase an equal number of shares at a combined price of $4.00 per share. The warrants will have an exercise price of $5.00 per share, exercisable immediately for five years after issuance.

The offering is expected to raise $21 million in gross proceeds before deducting underwriting discounts and expenses. The company plans to use the net proceeds for working capital and general corporate purposes, including the continued clinical development of their lead compound, Buntanetap. ThinkEquity is serving as the sole book-running manager for the offering, which is expected to close on February 4, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.47%
Tags
-
Rhea-AI Summary

Annovis Bio (NYSE: ANVS) has announced plans for an underwritten public offering of common stock and warrants. ThinkEquity will serve as the sole book-running manager, with a 45-day option to purchase up to an additional 15% of shares and/or warrants to cover over-allotments.

The company intends to use the proceeds primarily for working capital and general corporate purposes, including the continued clinical development of their lead compound, Buntanetap. The offering will be made through a shelf registration statement on Form S-3 filed with the SEC.

Annovis Bio is a late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative diseases, particularly Alzheimer's and Parkinson's disease. The completion and terms of the offering are subject to market conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.47%
Tags
Rhea-AI Summary

Annovis Bio (NYSE: ANVS) has been granted a U.S. patent for using buntanetap in the treatment and prevention of acute brain or nerve injuries. The patent, issued on January 2, 2025, extends the company's global protection, as similar patents have already been granted in the EU, Japan, and other regions worldwide.

The patent is based on buntanetap's capability to reduce neurotoxicity and mitigate neurodegenerative processes, making it potentially applicable to conditions such as stroke, ischemia, traumatic brain injury, micro infarcts, and other acute injuries. This expands the potential applications of buntanetap beyond its primary indications of Alzheimer's and Parkinson's diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
none
-
Rhea-AI Summary

Annovis Bio (NYSE: ANVS) announced that the FDA has accepted an updated protocol for its pivotal Phase 3 Alzheimer's Disease (AD) study, set to begin in January 2025. The revised protocol integrates two separate trials into a single 6/18-month trial. The original design included a 6-month symptomatic study and an 18-month disease-modifying study. Now, the consolidated protocol features a 6-month data readout focused on symptomatic effects, followed by an additional 12-month assessment for disease-modifying potential.

In October 2024, the FDA granted clearance for Annovis to proceed based on Phase 2/3 data showing cognitive improvement in early-stage AD patients. According to Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis, this streamlined approach will accelerate the development timeline while maintaining scientific rigor. The 6-month symptomatic data could potentially support a New Drug Application (NDA) filing, continuing seamlessly to evaluate long-term outcomes.

This development marks a significant step in advancing buntanetap as a novel treatment for AD, bringing the company closer to delivering new therapeutic options for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.61%
Tags
-
Rhea-AI Summary

Annovis Bio (NYSE: ANVS) recently showcased its breakthrough drug development for neurodegenerative diseases on Today's Marketplace. CEO Maria Maccecchini and Dr. Scott Shipman discussed the company's promising clinical trials targeting Alzheimer's and Parkinson's diseases.

The company's once-daily pill uniquely targets multiple toxic proteins, including plaques, tangles, and Lewy bodies that kill nerve cells in the brain. Clinical studies have demonstrated not just slowed progression but actual improvement in symptoms - enhanced cognition in early Alzheimer's patients and improved cognition and function in Parkinson's patients.

With over 7 million people affected by neurodegeneration in the United States, the impact extends beyond patients to caregivers and healthcare workers. The company is currently seeking funding for next-phase trials of this potentially groundbreaking treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.42%
Tags
none
Rhea-AI Summary

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company focused on neurodegenerative diseases, announces an upcoming live investor webcast on December 11, 2024, at 4:30 PM EST. Dr. Maria Maccecchini, Founder, President, and CEO, will present comprehensive updates on the company's achievements and future plans.

The webcast will cover key topics including updates on Phase 3 studies for Parkinson's and Alzheimer's diseases, FDA interactions, financial health, and strategic initiatives for 2025. Participants can submit questions in advance to ir@annovisbio.com for the Q&A session following the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.32%
Tags
conferences

FAQ

What is the current stock price of Annovis Bio (ANVS)?

The current stock price of Annovis Bio (ANVS) is $1.83 as of February 28, 2025.

What is the market cap of Annovis Bio (ANVS)?

The market cap of Annovis Bio (ANVS) is approximately 34.9M.

What is Annovis Bio, Inc.?

Annovis Bio, Inc. is a clinical-stage pharmaceutical company focused on developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's.

What is Buntanetap?

Buntanetap is Annovis Bio's leading drug candidate designed to inhibit multiple neurotoxic proteins, aiming to improve cognitive function in patients with neurodegenerative diseases.

Where is Annovis Bio headquartered?

Annovis Bio is headquartered in Malvern, Pennsylvania.

Who founded Annovis Bio?

Annovis Bio was founded by Dr. Maria Maccecchini, Ph.D., in 2008.

What are the key focus areas for Annovis Bio?

Annovis Bio focuses on developing drugs for Alzheimer’s Disease, Parkinson’s Disease, traumatic brain injury, stroke, and other neurodegenerative conditions.

What recent achievements has Annovis Bio accomplished?

Recent achievements include the completion of a Phase II/III study of Buntanetap in Alzheimer’s patients and the filing of a patent application for its use in treating neuropsychiatric conditions.

What are the financial highlights for Annovis Bio?

As of the first quarter of 2024, Annovis Bio reported $3.1 million in cash and continues to effectively manage its financial resources.

What is ANVS405?

ANVS405 is a drug in development by Annovis Bio for protecting the brain after traumatic brain injury and stroke.

What is ANVS301?

ANVS301 is an Annovis Bio drug in phase I clinical trials aimed at increasing cognitive capability in advanced stages of Alzheimer's Disease and dementia.

How can I learn more about Annovis Bio's developments?

For more information, visit Annovis Bio's official website at www.annovisbio.com and follow them on LinkedIn and X (formerly known as Twitter).
Annovis Bio Inc

NYSE:ANVS

ANVS Rankings

ANVS Stock Data

34.88M
16.67M
14.45%
6.65%
15.56%
Biotechnology
Pharmaceutical Preparations
Link
United States
MALVERN